Please login to the form below

Not currently logged in
Email:
Password:

biosimilars

This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

announced. Meanwhile, the FDA commissioner Scott Gottlieb has also this week launched another broadside against the industry, attacking its efforts to slow the arrival of biosimilars to market.

Latest news

More from news
Approximately 127 fully matching, plus 291 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    biosimilars could take up a portion of that, then it could create 15bn savings in Europe, if not more, ”. said Brault. “It is about increasing access. Bringing a biosimilar insulin to ... Brault added that the biosimilar launch would represent an

  • 30 Women Leaders in UK Healthcare

    Bringing people together to make things happen across organisational lines, Angela is leading projects to exploit real-world evidence, adaptive trials, accelerate the uptake of biosimilars and assist in Greater

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Alongside this, rumours that NHS England was planning to include biosimilars on the Accelerated Access Pathway, the flagship policy intervention designed to speed up the use of innovative products, would amount

  • The good, the bad and the ugly The good, the bad and the ugly

    These declines are driven by the patent expiry of Enbrel and subsequent brand erosion caused by the launch of biosimilars, ”says Annis. ... The rise of biosimilars is likely to present the main challenge to immunology products in 2018, particularly in

  • The tipping point The tipping point

    Driving disparity. If we look across Europe at biosimilar penetration, even the recently launched infliximab and etanercept biosimilars show highly variable uptake between markets. ... Once medical communities are ‘biosimilar experienced’there is

More from intelligence
Approximately 11 fully matching, plus 49 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop

  • PharmaLex appoints Zabin Younes as associate director PharmaLex appoints Zabin Younes as associate director

    She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years,

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    Novartis’generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS

  • Novimmune expands senior management team Novimmune expands senior management team

    Fleurant joins Novimmune with 20 years of quality expertise in life sciences, most recently having served as head of quality affairs at Alvotech, an Icelandic biosimilars specialist.

More from appointments
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest from PMHub

  • Biosimilars: Getting the flock to market

    The factor that drives the success of biosimilars is value. The biosimilar dividend is that more patients can get access to the high-value treatments they need. ... Luckily, the biosimilar path has already been trodden, so new agents can slipstream the

  • Webinar: What next for biosimilars?

    Webinar: What next for biosimilars? Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST. ... Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and

  • Video: Global Biosimilars Market

    Video: Global Biosimilars Market. Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch. ... It is predicted that

  • Tackling biosimilars – how to handle the threat to Pharma brands

    Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars. ... Therefore, while the biosimilar drugs may be very similar, they will never be identical.

  • Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

    Free Thinking: Are biosimilars the answer to the rising cost of RA treatment? ... With Enbrel biosimilar Benepali about to launch across EU, we ask what’ s next for RA?

More from PMHub
Approximately 17 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics